$504 Million is the total value of Rhenman & Partners Asset Management AB's 92 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 13.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALXN | Buy | Alexion Pharmaceuticals Inc | $16,846,000 | -11.7% | 121,000 | +21.0% | 3.34% | +16.0% |
| GILD | Buy | Gilead Sciences Inc | $16,535,000 | +31.8% | 180,000 | +45.2% | 3.28% | +73.0% |
| BMRN | Buy | BioMarin Pharmaceutical Inc | $15,671,000 | +26.8% | 190,000 | +61.0% | 3.11% | +66.5% |
| PFE | Buy | Pfizer Inc | $14,079,000 | -0.4% | 475,000 | +8.4% | 2.80% | +30.7% |
| LLY | Buy | Eli Lilly & Co | $14,042,000 | +14.1% | 195,000 | +33.6% | 2.79% | +49.8% |
| ALKS | Buy | Alkermes Plc | $13,847,000 | +10.4% | 405,000 | +156.3% | 2.75% | +45.0% |
| INCY | Buy | Incyte Corp Ltd | $12,320,000 | +3.3% | 170,000 | +54.5% | 2.45% | +35.6% |
| CELG | Buy | Celgene Corp | $12,011,000 | -3.6% | 120,000 | +15.4% | 2.38% | +26.6% |
| STJ | Buy | St Jude Medical Inc | $9,900,000 | -8.4% | 180,000 | +2.9% | 1.96% | +20.3% |
| BIIB | New | Biogen Inc | $9,892,000 | – | 38,000 | +100.0% | 1.96% | – |
| MDVN | Buy | Medivation Inc | $8,598,000 | +11.2% | 187,000 | +16.9% | 1.71% | +46.0% |
| HCA | Buy | HCA Holdings Inc | $8,117,000 | +25.0% | 104,000 | +8.3% | 1.61% | +64.1% |
| ALNY | Buy | Alnylam Pharmaceuticals Inc | $7,846,000 | +34.4% | 125,000 | +101.6% | 1.56% | +76.3% |
| ENDP | Buy | Endo International Plc | $7,319,000 | +3.1% | 260,000 | +124.1% | 1.45% | +35.3% |
| ESRX | Buy | Express Scripts Hg Co | $7,281,000 | +12.6% | 106,000 | +43.2% | 1.44% | +47.8% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $6,200,000 | -12.0% | 78,000 | +39.3% | 1.23% | +15.6% |
| COO | Buy | Cooper Companies Inc (The) | $6,159,000 | +24.0% | 40,000 | +8.1% | 1.22% | +62.8% |
| ABC | Buy | AmerisourceBergen Corp | $5,453,000 | +14.3% | 63,000 | +37.0% | 1.08% | +50.1% |
| CPHD | Buy | Cepheid Inc | $5,004,000 | +82.6% | 150,000 | +100.0% | 0.99% | +139.9% |
| EW | Buy | Edwards Lifesciences Corp | $4,852,000 | +25.4% | 55,000 | +12.2% | 0.96% | +64.6% |
| CERN | Buy | Cerner Corp | $4,555,000 | -7.7% | 86,000 | +4.9% | 0.90% | +21.2% |
| ZLTQ | Buy | ZELTIQ Aesthetics Inc | $4,346,000 | +19.0% | 160,000 | +25.0% | 0.86% | +56.3% |
| CYH | Buy | Community Health Syst Inc | $4,165,000 | +65.3% | 225,000 | +136.8% | 0.83% | +117.1% |
| HALO | Buy | Halozyme Therapeutics Inc | $4,082,000 | -42.5% | 431,000 | +5.1% | 0.81% | -24.6% |
| ARIA | Buy | Ariad Pharmaceuticals Inc | $3,834,000 | +42.6% | 600,000 | +39.5% | 0.76% | +87.4% |
| LIVN | Buy | Livanova Plc | $3,779,000 | -3.5% | 70,000 | +6.1% | 0.75% | +26.7% |
| ELGX | Buy | Endologix Inc | $3,637,000 | -12.5% | 435,000 | +3.6% | 0.72% | +14.8% |
| HZNP | Buy | Horizon Pharma Plc | $3,314,000 | +4.7% | 200,000 | +37.0% | 0.66% | +37.7% |
| RDUS | New | Radius Health Inc | $3,301,000 | – | 105,000 | +100.0% | 0.66% | – |
| HTWR | Buy | Heartware Intl Inc | $3,142,000 | -7.0% | 100,000 | +49.3% | 0.62% | +22.1% |
| OMCL | Buy | Omnicell Inc | $3,066,000 | +33.3% | 110,000 | +48.6% | 0.61% | +75.0% |
| LBIO | Buy | Lion Biotechnologies Inc | $3,048,000 | -31.3% | 600,000 | +4.3% | 0.60% | -9.8% |
| DVAX | Buy | Dynavax Technologies Corp | $2,886,000 | +117.2% | 150,000 | +172.7% | 0.57% | +185.1% |
| XNCR | Buy | Xencor Inc | $2,684,000 | +1.2% | 200,000 | +10.3% | 0.53% | +32.9% |
| EXEL | Buy | Exelixis Inc | $2,600,000 | +0.2% | 650,000 | +41.3% | 0.52% | +31.6% |
| CMRX | Buy | Chimerix Inc | $2,555,000 | +11.5% | 500,000 | +95.3% | 0.51% | +46.5% |
| ESPR | Buy | Esperion Therapeutics Inc | $2,537,000 | +14.0% | 150,000 | +50.0% | 0.50% | +49.6% |
| RARE | New | Ultragenyx Pharmaceutical Inc | $2,532,000 | – | 40,000 | +100.0% | 0.50% | – |
| FGEN | Buy | FibroGen Inc | $2,427,000 | +59.3% | 114,000 | +128.0% | 0.48% | +109.6% |
| NBIX | New | Neurocrine Biosciences Inc | $2,373,000 | – | 60,000 | +100.0% | 0.47% | – |
| MGNX | Buy | Macrogenics Inc | $2,250,000 | -22.7% | 120,000 | +27.7% | 0.45% | +1.6% |
| PTLA | Buy | Portola Pharmaceuticals Inc | $2,142,000 | -32.9% | 105,000 | +69.4% | 0.42% | -11.8% |
| PCRX | Buy | Pacira Pharmaceuticals Inc | $2,119,000 | -21.2% | 40,000 | +14.3% | 0.42% | +3.7% |
| HOLX | Buy | Hologic Inc | $2,070,000 | +60.7% | 60,000 | +80.2% | 0.41% | +110.8% |
| RIGL | Buy | Rigel Pharmaceuticals Inc | $1,768,000 | -30.9% | 850,000 | +0.7% | 0.35% | -9.3% |
| CATB | Buy | Catabasis Pharmaceuticals Inc | $1,739,000 | -28.4% | 345,100 | +12.7% | 0.34% | -6.0% |
| ANTH | Buy | Anthera Pharmaceuticals Inc | $1,575,000 | +35.8% | 435,000 | +74.0% | 0.31% | +78.9% |
| TTPH | Buy | Tetraphase Pharmaceuticals Inc | $1,389,000 | -38.5% | 300,000 | +33.3% | 0.28% | -19.1% |
| NVRO | New | Nevro Corp | $1,125,000 | – | 20,000 | +100.0% | 0.22% | – |
| OREX | Buy | Orexigen Therapeutics Inc | $675,000 | -67.0% | 1,200,000 | +0.9% | 0.13% | -56.6% |
| OCUL | New | Ocular Therapeutix Inc | $386,000 | – | 40,000 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-04-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 43 | Q2 2024 | 5.1% |
| BIOMARIN PHARMACEUTICAL INC | 43 | Q2 2024 | 5.0% |
| ALKERMES PLC | 43 | Q2 2024 | 3.3% |
| LILLY ELI & CO | 42 | Q2 2024 | 5.8% |
| INTRA-CELLULAR THERAPIES INC | 42 | Q2 2024 | 2.4% |
| VERTEX PHARMACEUTICALS INC | 41 | Q2 2024 | 4.3% |
| REVANCE THERAPEUTICS INC | 41 | Q2 2024 | 0.9% |
| ABBVIE INC | 40 | Q2 2024 | 4.4% |
| CVS HEALTH CORP | 40 | Q4 2023 | 3.5% |
| JAZZ PHARMACEUTICALS PLC | 40 | Q2 2024 | 3.1% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-13 |
| 13F-HR | 2024-08-13 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.